Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P05976
UPID:
MYL1_HUMAN
Alternative names:
Myosin light chain alkali 1/2
Alternative UPACC:
P05976; B2R4N6; B2R4T6; P06741; Q6IBD5
Background:
Myosin light chain 1/3, also known as Myosin light chain alkali 1/2, plays a pivotal role in skeletal muscle function. It is essential for the proper formation and maintenance of myofibers, contributing to muscle strength and coordination. This protein's significance is underscored by its involvement in muscle contraction mechanisms, facilitating the interaction between myosin and actin filaments.
Therapeutic significance:
Linked to Congenital myopathy 14, a severe muscle disorder characterized by muscle weakness, respiratory failure, and delayed motor development, Myosin light chain 1/3's study is crucial. Understanding its function and the impact of genetic variants can lead to targeted therapies, offering hope for patients suffering from this debilitating condition.